#USA #Orlando, Florida #Nordic Pharma #LACRIFILL #Dry Eye

Nordic Pharma Unveils LACRIFILL Gel at American Academy of Ophthalmology 2025

Nordic Pharma, a subsidiary of Nordic Group B.V., is gearing up to make waves at the upcoming 2025 American Academy of Ophthalmology (AAO) conference, scheduled to take place from October 18 to 20 in Orlando, Florida. The company will feature its innovative product, the LACRIFILL Canalicular Gel, designed specifically for treating dry eye symptoms. During the event, Nordic Pharma will unveil valuable patient data and share groundbreaking findings from recent studies that highlight the patient experience with LACRIFILL.

This announcement is significant as dry eye has become an increasingly prevalent condition affecting various individuals. According to Jai Parekh, MD, MBA, Chief Commercial Officer at Eye Care U.S., the response to LACRIFILL has been overwhelmingly positive, with an impressive 98.11% of first-time or repeat survey respondents indicating their willingness to return for more doses of the gel.

The conference will provide an excellent platform for industry professionals to learn about various ophthalmic innovations benefiting patients. Nordic Pharma is committed to educating healthcare providers about the positive impacts of LACRIFILL on both patient health and practice efficiency. To further this mission, Nordic Pharma has enlisted experts like Vance Thompson, MD, Kayla Karpuk, OD, and Mark Packer, MD to contribute to a critical publication that will discuss lacrimal occlusion within the contexts of cataract surgery and refractive surgery, to be featured in the Expert Review of Ophthalmology.

In his commentary, Dr. Thompson emphasized the crucial role of managing dry eye conditions when it comes to preoperative planning, surgical outcomes, patient recovery, and overall satisfaction following advanced cataract and refractive surgeries. He noted that LACRIFILL meets a critical niche as it is indicated for use up to six months, making it suitable for preoperative applications to optimize the ocular surface and maintain postoperative benefits.

On October 18, the conference will host the Women in Ophthalmology (WIO) awards ceremony and networking reception at 5:30 PM, where Nordic Pharma will proudly serve as the main sponsor for the second consecutive year. Lisa M. Nijm, MD, JD, CEO of WIO, expressed gratitude for Nordic Pharma's ongoing support, which honors outstanding women in ophthalmology and advances the organization's mission to improve the professional environment for female ophthalmologists.

Conference attendees are encouraged to visit booth 1401, where they will have the opportunity to experience demo sessions for injection techniques and place orders directly from the exhibit.

According to the newly released TFOS Dry Eye Workshop (DEWS) III Report, Nordic Pharma's reticulated hyaluronic acid (HA)-based canalicular filler gel features prominently, with references citing its efficacy in improving corneal staining, Schirmer test results, and other metrics after three months of administration. A comparative study revealed that LACRIFILL was safe, well-tolerated, and demonstrated statistically significant improvements in dry eye disease symptoms and signs sustained over six months.

To learn more about LACRIFILL and to place orders for the product, interested parties can visit lacrifill.com.

About Nordic Group B.V.

Nordic Group B.V. is a mid-sized international pharmaceutical company dedicated to developing and marketing specialized products. The company has significantly expanded its portfolio through focused development and strategic acquisitions, establishing a solid foundation within eye care, rheumatology, and women's health. With deep roots across Europe, Nordic Group has recently broadened its global reach through additional acquisitions.

As part of SEVER Life Sciences, a holding company established in 2019, Nordic Group consists of three complementary organizations that provide a wide array of products, pharmaceutical development services, and advanced administration technologies.

About Nordic Pharma, Inc.

Nordic Pharma, Inc., the American affiliate of Nordic Group B.V., partners with established global biopharmaceutical firms and is uniquely positioned to leverage its expertise in the market introduction of biotechnology-derived drugs, sterile manufacturing, and other advanced technologies.

_Note: This press release contains forward-looking statements regarding Nordic Group/Nordic Pharma's business developments and strategic initiatives. Actual results may differ as a result of various risks and uncertainties._